Publications by authors named "Branquinho D"

Article Synopsis
  • Etrasimod is a selective oral drug that has been linked to a potential increased risk of macular edema, a condition affecting the eye.
  • In a clinical study focusing on patients with conditions like ulcerative colitis and Crohn's disease, the rate of macular edema associated with etrasimod was similar to that of a placebo, with very few cases reported.
  • Overall, macular edema and other eye-related issues were rare among patients taking etrasimod, and most related side effects were not serious.
View Article and Find Full Text PDF
Article Synopsis
  • Histologic remission is an important treatment goal in ulcerative colitis (UC) and could lead to better long-term health outcomes, with etrasimod being an oral medication studied for its effectiveness in treating active UC.
  • In a study, patients were given either etrasimod or a placebo, and their improvement in disease symptoms and histologic endpoints were evaluated at 12 and 52 weeks.
  • Results showed that those on etrasimod had significantly better outcomes in terms of histologic and composite measures, with a higher percentage achieving clinical remission if they experienced disease clearance at the earlier 12-week mark.
View Article and Find Full Text PDF
Article Synopsis
  • * Both groups had similar rates of all infections, serious infections, herpes zoster, and opportunistic infections, with very few occurrences in either group.
  • * The study also noted that low lymphocyte counts (ALC <0.2) did not correlate with serious infections, indicating that etrasimod may be a safe option for patients with UC regarding infection risk.
View Article and Find Full Text PDF

Introduction: () infection is highly prevalent in Portugal and its eradication is formally recommended. However, the indiscriminate use of antimicrobials has led to a drastic rise in antibiotic resistance, with the failure of traditional eradication schemes. A single-capsule bismuth-based quadruple therapy became recently available in Portugal.

View Article and Find Full Text PDF

Background: Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab.

Methods: We conducted an open-label single-arm multicentre prospective study.

View Article and Find Full Text PDF

Background And Aims: Golimumab has an established exposure-response relationship in patients with ulcerative colitis [UC]. However, the association of serum golimumab trough levels [TL] with objective markers of disease activity, such as endoscopic and histological activity scores and concentrations of biomarkers, remains less understood. This report describes the relationship of serum golimumab TL at the end of the induction period [Week 6] with clinical, endoscopic, histological, and biomarker parameters.

View Article and Find Full Text PDF

Rupture of pseudoaneurysms is rare but can be life-threatening complications of acute or chronic pancreatitis, usually due to enzymatic digestion of vessel walls crossing peripancreatic fluid collections. We report the case of a 40 year-old female, with multisystemic lupus and anticoagulated for prior thrombotic events, admitted for probable cyclosporine-induced acute pancreatitis. Hemodynamic instability occurred due to abdominal hemorrhage from two pseudoaneurysms inside an acute peri-pancreatic collection.

View Article and Find Full Text PDF

Background: Helicobacter pylori eradication rates with standard triple therapy in many countries are clinically unacceptable. Fluoroquinolone resistance is increasing and jeopardizing second-line regimens. There is a growing need for an effective strategy in patients who failed previous therapies.

View Article and Find Full Text PDF

Background: Helicobacter pylori eradication rates in Portugal are declining, due to increased resistance of this bacterium to antimicrobial agents, especially Clarithromycin. Quadruple Levofloxacin-containing regimens could be an option for first-line treatment, but its efficacy should be evaluated as fluoroquinolone resistance is rapidly increasing. Our aim was to compare the efficacy of Clarithromycin and Levofloxacin-based sequential quadruple therapies as first-line treatment options and determine factors associated with treatment failure.

View Article and Find Full Text PDF

Due to the overwhelming burden of colorectal cancer (CRC), great effort has been placed on identifying genetic mutations that contribute to disease development and progression. One of the most studied polymorphisms that could potentially increase susceptibility to CRC involves the nucleotide-binding and oligomerization-domain containing 2 (NOD2) gene. There is growing evidence that the biological activity of NOD2 is far greater than previously thought and a link with intestinal microbiota and mucosal immunity is increasingly sought after.

View Article and Find Full Text PDF

A 45-year-old man presented with follicular exanthema in his lower limbs, alternating bowel habits and significant weight loss. His medical history included seronegative arthritis, bipolar disease and an inconclusive diagnostic laparoscopy. Diagnostic work up revealed microcytic anaemia and multivitamin deficiency.

View Article and Find Full Text PDF

Actinomyces meyeri is a Gram-positive anaerobic forming bacterium of the genus Actinomyces, part of the oral cavity's flora, and its classification remains an unresolved issue. It is an extremely rare cause of disease, occurring in middle-aged immunocompetent patients and frequently misdiagnosed as malignancy or lung abscess. A 56-year-old man diagnosed with oesophageal squamous cell carcinoma had an endoscopically placed stent to palliate his dysphagia.

View Article and Find Full Text PDF